All In Biotech

Drug Trial Radar · NCT07163624

UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of UBT251 Injection in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 211 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

211

Actual

Start

Mar 22, 2025

Primary completion

Nov 21, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • UBT251 Injection 2.0 mg and UBT251 Injection PlaceboDrug

    UBT251 Injection and UBT251 Injection Placebo once weekly

  • UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection PlaceboDrug

    UBT251 Injection and UBT251 Injection Placebo once weekly

  • UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection PlaceboDrug

    UBT251 Injection and UBT251 Injection Placebo once weekly

  • UBT251 Injection 6.0 mg and UBT251 Injection PlaceboDrug

    UBT251 Injection and UBT251 Injection Placebo once weekly

  • Semaglutide Injection (Ozempic®)Drug

    Semaglutide Injection (Ozempic®) once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c at Week 24Time frame: Baseline to week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The United Bio-Technology (Hengqin) Co., Ltd.

    Zhuhai, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.